0

Category: CMHC

Cardiometabolic Health Congress

Insulin Degludec/Liraglutide 1 Step Closer to US FDA Approval

An FDA advisory committee has voted unanimously in favor of approval of the combination type 2 diabetes treatment insulin degludec/liraglutide. The panel also agreed that the combination treatment would at least be appropriate for patients who had previously used an insulin analogue or GLP-1 agonist, but no other consensus was reached regarding which patient types would be suitable candidates. Members of the advisory committee indicated the combination treatment was needed and expressed hope an insulin-containing combination might overcome “insulin inertia” among clinicians.

Medscape Medical News. FDA panel backs Novo Nordisk Insulin-GLP-1 Combination IDegLira. May 25, 2016.

Share onShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

History of the Cardiometabolic Health Congress (CMHC)

The Cardiometabolic Health Congress launched in October 2006 in Boston and since then has grown to become the largest US-based, multidisciplinary conference addressing cardiometabolic disease prevention and management through an integrated approach to education. Now in its 11th year, CMHC Boston is held each October and attended by 1300+ mid to advanced level healthcare professionals seeking real-world solutions to integrate directly into their clinical practices. The goal of the CMHC is to improve patient outcomes through early identification and intervention strategies for patients with, or at risk of developing, cardiovascular and metabolic disease.

Read more

Share onShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

Men’s Weight Impacts Epigenetic Markers on Sperm Cells, Likely to Affect Health of Future Children

The study consisted of 13 men with a BMI of 22.9 and 10 men with a BMI of 31.8. In the first part of the study, the researchers found that sperm from obese men had a distinct epigenetic signature in comparison to the normal weight men, particularly at genes that control brain development and function. In the second part of the study, the researchers observed 6 men before and up to a year after they had undergone bariatric surgery. Within weeks, 3000 differences in epigenetic patterns of the men’s sperm were seen, and after a year, as their diet and lifestyle improved, there were upwards of 5000 changes. Differences were particularly noted at gene regions associated with central control of appetite. These results, according to the researchers, demonstrate that the epigenetic landscape of human sperm is dynamic and vulnerable to environmental changes.

“It’s another critical piece of information that informs us about the very real need to look at the preconception health of fathers,” said Ida Donkin, MD in a press release, one of the authors of the study. “And it’s a message we need to disseminate in society.”

Learn more when CMHC faculty member Harold Bays, MD, an expert in obesity and how epigenetics contribute to obesity as a “transgenerational” disease, speaks at the inaugural CMHC West March 4-5, 2016 in San Francisco on “Treating Obesity Seriously: How Genetics and Epigenetic Factors Affect Weight.” (Also visit the CMHC website to view Dr. Bays’s presentation from the 10th Annual CMHC.)

Reference:
Donkin et al. Obesity and bariatric surgery drive epigenetic variation of spermatozoa in humans. Cell Metabolism. http://dx.doi.org/10.1016/j.cmet.2015.11.004 .

Share onShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

FDA Grants Approval for Two New Insulin Therapies

Two new insulin formulations were recently granted FDA approval: Tresiba® (insulin degludec), a long-acting insulin analog that can be administered once daily any time of day, and Ryzodeg®, a combination of insulin degludec and rapid-acting insulin aspart that is taken once or twice per day with any main meal. Both are indicated for adults with type 1 and 2 diabetes.

The approvals add to a growing list of insulin options for patients with diabetes. Toujeo® (insulin glargine U300) was approved earlier this year and Afrezza®, the only inhaled insulin available in the US, reached pharmacies in February. Learn more about these newest options and how they can help you customize your patients’ insulin regimens at the 10th Annual CMHC. On Friday, October 23, Dr. Matthew Riddle will chair the symposium, “Paving the Way to Patient Acceptance, Adherence and Satisfaction: The Role of Next-Generation Insulin Therapies,” and Dr. Anne Peters will chair “The Evolution of Insulin Therapy: New Developments in Treatment, Technology, and Methods of Administration” on Saturday, October 24. Read more

Share onShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

First Fully Mobile Continuous Glucose Monitor Gets FDA Approval

The US FDA has just approved the first and only fully mobile continuous glucose monitoring system for both adults and children as young as 2 years of age. The system sends glucose information in real time directly to an app on iOS-enabled devices, such as the iPhone, using Bluetooth technology. (Android applications are expected early next year.) The Dexcom G5 Mobile CGM System allows for up to 5 “followers,” such as parents or other caregivers, to remotely monitor the patient’s glucose levels and receive alerts about readings of concern.

To learn more on innovations such as these, join us at #CMHC 2015 on Saturday, October 24 for “Advances in Diabetes Technology,” to be presented during the Diabetes Management session by expert faculty speaker Anne L. Peters, MD.

Read more here.

Share onShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn